297 related articles for article (PubMed ID: 31331645)
21. A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia.
Wang X; Wang Y; Li L; Xue X; Xie H; Shi H; Hu Y
Oncogene; 2020 Feb; 39(9):1860-1874. PubMed ID: 31784651
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
23. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
24. Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.
Liu Y; Lu M; Chen J; Li S; Deng Y; Yang S; Ou Q; Li J; Gao P; Luo Z; Yuan P; Tan J; Gao X
Sleep Breath; 2022 Jun; 26(2):893-906. PubMed ID: 34254261
[TBL] [Abstract][Full Text] [Related]
25. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
[TBL] [Abstract][Full Text] [Related]
26. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
27. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
28. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
[TBL] [Abstract][Full Text] [Related]
29. [Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].
Shi Y; Lv W; Wang L; Hu J
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):781-786. PubMed ID: 29167009
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Fournel L; Wu Z; Stadler N; Damotte D; Lococo F; Boulle G; Ségal-Bendirdjian E; Bobbio A; Icard P; Trédaniel J; Alifano M; Forgez P
Cancer Lett; 2019 Nov; 464():5-14. PubMed ID: 31404614
[TBL] [Abstract][Full Text] [Related]
31. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
32. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy upregulates expression of HIF-1α and PD-L1 in related pathways and its clinical relevance in non-small-cell lung cancer.
Sun W; Cheng Y; Ma X; Jin Z; Zhang Q; Wang G
Eur J Med Res; 2024 Apr; 29(1):230. PubMed ID: 38609977
[TBL] [Abstract][Full Text] [Related]
34. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
[TBL] [Abstract][Full Text] [Related]
35. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
36. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
[TBL] [Abstract][Full Text] [Related]
37. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
39. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
